Cite
Timme N, Han Y, Liu S, et al. Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. Transl Oncol. 2019;13(2):221-232doi: 10.1016/j.tranon.2019.09.013.
Timme, N., Han, Y., Liu, S., Yosief, H. O., García, H. D., Bei, Y., Klironomos, F., MacArthur, I. C., Szymansky, A., von Stebut, J., Bardinet, V., Dohna, C., Künkele, A., Rolff, J., Hundsdörfer, P., Lissat, A., Seifert, G., Eggert, A., Schulte, J. H., Zhang, W., & Henssen, A. G. (2020). Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. Translational oncology, 13(2), 221-232. https://doi.org/10.1016/j.tranon.2019.09.013
Timme, Natalie, et al. "Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors." Translational oncology vol. 13,2 (2020): 221-232. doi: https://doi.org/10.1016/j.tranon.2019.09.013
Timme N, Han Y, Liu S, Yosief HO, García HD, Bei Y, Klironomos F, MacArthur IC, Szymansky A, von Stebut J, Bardinet V, Dohna C, Künkele A, Rolff J, Hundsdörfer P, Lissat A, Seifert G, Eggert A, Schulte JH, Zhang W, Henssen AG. Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. Transl Oncol. 2020 Feb;13(2):221-232. doi: 10.1016/j.tranon.2019.09.013. Epub 2019 Dec 21. PMID: 31869746; PMCID: PMC6931204.
Copy
Download .nbib